Telix Pharmaceuticals (TLX) Total Liabilities (2023 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Total Liabilities for 3 consecutive years, with $748.6 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 20.73% to $748.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $748.6 million through Dec 2025, up 20.73% year-over-year, with the annual reading at $748.6 million for FY2025, 27.44% up from the prior year.
  • Total Liabilities for Q4 2025 was $748.6 million at Telix Pharmaceuticals, up from $620.1 million in the prior quarter.
  • The five-year high for Total Liabilities was $748.6 million in Q4 2025, with the low at $167.3 million in Q4 2023.
  • Average Total Liabilities over 3 years is $512.0 million, with a median of $620.1 million recorded in 2024.
  • The sharpest move saw Total Liabilities soared 270.57% in 2024, then rose 20.73% in 2025.
  • Over 3 years, Total Liabilities stood at $167.3 million in 2023, then skyrocketed by 270.57% to $620.1 million in 2024, then increased by 20.73% to $748.6 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $748.6 million, $620.1 million, and $167.3 million for Q4 2025, Q4 2024, and Q4 2023 respectively.